TW200526246A - Medicament comprising inhibitors of long pentraxin PTX3 - Google Patents
Medicament comprising inhibitors of long pentraxin PTX3 Download PDFInfo
- Publication number
- TW200526246A TW200526246A TW093137054A TW93137054A TW200526246A TW 200526246 A TW200526246 A TW 200526246A TW 093137054 A TW093137054 A TW 093137054A TW 93137054 A TW93137054 A TW 93137054A TW 200526246 A TW200526246 A TW 200526246A
- Authority
- TW
- Taiwan
- Prior art keywords
- arthritis
- ptx3
- patent application
- disease
- scope
- Prior art date
Links
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title claims abstract description 32
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title claims abstract description 32
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 210000000845 cartilage Anatomy 0.000 claims abstract description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract 2
- 206010003246 arthritis Diseases 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000036487 Arthropathies Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000012659 Joint disease Diseases 0.000 claims description 4
- 208000015100 cartilage disease Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- 206010031264 Osteonecrosis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 206010071578 autoimmune retinopathy Diseases 0.000 claims description 3
- 201000007327 bone benign neoplasm Diseases 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 201000001223 septic arthritis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 2
- 208000001848 dysentery Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 description 2
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 description 2
- 206010057178 Osteoarthropathies Diseases 0.000 description 2
- 108700025763 PTX3 Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 101150095640 PTX3 gene Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
Description
200526246 (1) 九、發明說明 【發明所屬之技術領域】 本文所述本發明係有關長賓特辛PTX3的抑制劑對於 製備治療自體免疫性疾病與骨骼和軟骨的退化疾病所用藥 •劑之用途。 【先前技術】 PTX3爲一種糖蛋白，能夠自然地自己組織或由二硫 化橋聯維持在一起的同元十體物結構（homodecameric structure )，其可在多種細胞類型內表現（Bottazzi，et al·，J. Biol. Chem·，1997; 272: 32817-32823)，特別是 在暴露於炎性細胞介質間白素1 b e t a ( I L — 1 b e t a )與腫 瘤壞死因子a ( TNF — a )之後於單核型吞噬物細胞和內 皮細胞內表現。 PTX3包括二個結構功能部位，一爲與任何已知分子 不相關的N -端，及另一爲類似於短賓特辛例如C -反應 性蛋白（CRP )的C 一端。於人類PTX3 ( hPTX3 )與動物 PTX3之間有實質的相似性存在。 有關賓特辛的總評，可參看 H. Gewurz， et al.， Current Opinion in Immunology, 1995，7 ： 54 — 64 o 重組型PTX3與由初級細胞（如纖維母細胞，內皮細 胞和天賦免疫細胞）所表現的PTX3兩者之間都是主要組 織成爲由二硫化橋聯所穩定化的十體物結構體。PTX 3的 單一單體物具有約4 5 k D a的分子量，可從該十體物型蛋白 200526246 (2) 質透過二硫化橋聯的還原接著單體物間交互作用中涉及的 經還原本胱胺酸烷基化而得而得或透過彼等的部位特異性 突變生成而得（Battazzi，et al·，J· Biol. Chem” 1997; 272 :3 2 8 1 7 - 3 2823 ) ° 對於患有風濕性關節炎的病人所作的最近硏究顯示出 在滑液內 PTX3表現水平有明顯的增力日。此增加的 PTX3 表現關聯於此疾病特性中的炎性程序（Lucchetti, et al·， Clin. Exp. Immunol. 2000; 1 1 9: 1 96-202 ) 0 WO 0 3 /0 8 63 8 0述及PTX3基因表現抑制劑對於自體免 疫性疾病，包括風濕性關節炎的治療之用途。 WO 0 3 /0 863 8 0與本發明不同之處在於其所面對者爲 相對於本發明中所述化合物和抑制方法爲完全不同的化合 物與完全不同的抑制方法之用途。 事實上，於本專利申請中，係述及能夠直接抑制蛋白 質（PTX3 )生物學活性物的PTX3拮抗齊U。 諳於此技者都熟悉下述事實，亦即用小分子來調節（ 以選擇性方式）基因表現，例如不改變發炎所涉及的其他 基因之表現者，如在WO 03 /0 8 63 8 0中所槪述者，可能爲 困難者。再者，對於在重要生物學功能上起基本作用的蛋 白質之表現，在基因層次上給予抑制也可能促成非所欲之 效應，例如，對於感染和生殖力的敏感性之增加。 於醫學領域中，因而對於能夠作爲P TX 3拮抗劑的其 他抑制劑（彼等可用來根據本發明治療疾病）之可取得性 保持著強烈感知之需求。 -6- 200526246 (3) 【發明內容】 頃發現PTX3的抑制劑或拮抗劑可用來預防和治療自 體免疫性疾病與骼和軟骨的退化性疾病。 本發明PTX3抑制劑的一非限制性例子爲單株或多株 抗一 PTX3抗體，而本發明PTX3拮抗劑的一非限制性例子 爲單體型PTX3或其肽或肽模擬性衍生物。 本發明的目標因而爲能夠阻抗長賓特辛P TX 3所具生 物學活性的長寡特辛PTX3之抑制劑或拮抗劑對於因爲製 備治療選自下列所構成的群組中之自體免疫性疾病所用藥 劑之用途：系統性紅斑狼瘡（S LE )、多發性硬化（MS ) 、關節炎、糖尿病、甲狀腺炎、溶血性貧血、萎縮性睪九 炎、Good pasture氏病、自體免疫性視網膜病、自體免疫 性血小板減少症、重症肌無力、原發性膽硬化、慢性攻擊 性肝炎、漬瘍性結腸炎、皮炎、慢性血管球性腎炎、 SjSgren氏徵候群、Reiter氏徵候群、肌炎、系統性硬化 及多關節炎；及用爲製備治療選自下列所構成的群組中之 退化性骨骼和軟骨所用藥劑之用途：骨關節炎；骨關節病 ;關節退化病；膠原缺乏；具有軟骨內軟化的特徵之軟骨 或骨骼疾病；原發性關節炎，包括，例如，風濕性關節炎 '幼年型關節炎、未分化型慢性關節炎；和多關節炎；自 體免疫源的繼發性關節炎，包括，例如，系統性紅斑狼瘡 、牛皮癬性關節炎、Crohn氏病關節炎；代謝不全性來源 之關節炎，包括，例如，尿酸一鈉關節病、焦磷酸鹽關節 >7- 200526246 (4) 病、草酸鈣關節病；傳染性關節炎、因骨質疏鬆所致關節 炎、無菌性骨壞死、良性和惡性骨腫瘤。 【實施方式】 發明詳細說明 ”長賓特辛PTX3抑制劑”意指不論其天然（人類或動 物），重組或合成來源爲何，能夠結合P TX 3且阻抗其生 物學活性的任何單株或多株抗體。 本發明單株抗體製備之一例子爲Godine, J. W., 1986, 在 Monoclonal Antibodies: Principle and Practice.
Academic Press，San Diego中所述及者，而本發明多株抗 體製備之一例子爲 Harlow E. and Lane D·，在 Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory， 1988; Cold Spring Harbor，NY 中所述者。 ’’單體物型賓特辛”意指不論其天然（人類或動物）， 重組合成來源的任何單體物型賓特辛。 ’’單體物型賓特辛的衍生物”意指該單體物型賓特辛的 載有至少一突變且保持著選擇性抑制P TX 3活性的官能能 力之官能類似物’或指能夠模擬p TX 3所具線型或構型功 能部位且保持著選擇性抑制PTX3活性的官能能力之肽或 肽模擬性類似物。 較佳的單體物型賓特辛之類型爲人類單體物型賓特辛 ，其序列載於WO 99/32516之中。 與PTX3異常性活化相關的自體免疫性疾病爲包括在 -8 - 200526246 (5) 下列所構成的群組之中者：系統性紅斑狼瘡（SLE )、多 發性硬化（M S )、關節炎、糖尿病、甲狀腺炎、溶血性 貧血、萎縮性睪九炎、Good pasture氏病、自體免疫性視 網膜病、自體免疫性血小板減少症、重症肌無力、原發性 膽硬化、慢性攻擊性肝炎、潰瘍性結腸炎、皮炎、慢性血 管球性腎炎、Sj0gren氏徵候群、Reiter氏徵候群、肌炎 、系統性硬化及多關節炎。 與P T X 3異當性活化相關的退化性骨和軟骨疾病爲包 括在下列所構成的群組之中者：骨關節炎；骨關節病；關 節退化病；膠原缺乏；具有軟骨內軟化的特徵之軟骨或骨 黯疾病；原發性關節炎，包括，例如，風濕性關節炎、幼 年型關節炎、未分化型慢性關節炎；和多關節炎；自體免 疫源的繼發性關節炎，包括，例如，系統性紅斑狼，瘡、牛 皮癬性關節炎、Crohn氏病關節炎；代謝不全性來源之關 節炎’包括，例如，尿酸—鈉關節病、焦磷酸鹽關節病、 草酸錦關節病；傳染性關節炎、因骨質疏鬆所致關節炎、 無菌性骨壞死、良性和惡性骨腫瘤。 下面的實施例進一步闡述本發明。 實施例1 於一膠原誘發關節炎（CIA)小鼠模型中使用ρτΧ3 — 缺乏性小鼠（Campbell，et al·，Eur. j. Immunol，2〇〇〇; 30 1 5 6 8 7 5 )。貫驗的目標爲評估p τ χ 3 — / 一小鼠對於關 節炎表現型的透導之敏感性。 200526246 (6) 對129sv χ C57BL/6 P T X 3 - / -小鼠使用1 〇 〇微克雞第 Π型膠原（SIGMA)在完全Freund’s佐劑中且加入250微 克經熱抑活化的結核分枝桿菌（M. tuberculosis)，總體 積1 0 0微體，經由在接近尾巴區的多次皮下注射予以處理 ， 〇 於2 1天後重複相同的處理。 於給藥期結束時，使用計及發炎關節的存在及彼等的 大小之隨意計分系統評估關節炎的發生率及嚴重性。所得 φ 結果呈現於表1之中。 於表1中所報告的在PTX 3 +/ +小鼠體內之較大疾病發 生率提供出PTX3 -/•小鼠對膠原誘導關節炎的發展爲較小 敏感之證據。此發現亦由顯示出在PTX3 +/ +小鼠體內的關 節炎比在PTX3 小鼠體內者有較大嚴重性之臨床評分所 確定。 所得結果表明P T X 3或其抑制的不存在可用來預防和 治療骨骼和軟骨的炎性及/或退化性疾病。 g 表1 在 PTX3+/ +和 PTX3-/-小 鼠體內的膠原誘發關節炎 動物 發生率* 臨床計分 PTX3+/ + 3/5 1 0 PX3-/- 3/7 3.6 於實驗結束的發生率（第一次免疫化的6 0天後）。 在實驗結束時有關節炎的動物之平均臨床評分。 -10- 200526246 (7) 附註：於第二次免疫化後，四肢關節炎臨床微像的# 在係每一星期評估二次。每一肢係以從1至4評分；每— 動物因而可得最大評分値1 6。 有關工業應用性方面，單體物型賓特辛PTX3或其月太 或肽模擬衍生物或抗-賓特辛PTX3抗體都可呈藥學,組成 物形式’其中係以藥學可接受之賦形劑及/或稀釋劑，例 如無菌水、羧甲基纖維素或此領域中的專業者所知的其他 賦形劑將活性成分溶解化及/或賦形化。 可用於單體物型賓特辛的藥學組成物之例子爲與在 WO 99/3 25 1 6中對長賓特辛PTX3所述者相同。 根據本發明的化合物可經腸或非經腸途徑給用，特別 較佳的藥學形式爲慢釋放性植體或關節內注射形式。 每曰劑量係決定於主治醫師的判斷，病人的體重，年 齡和一般狀況。 必須提及者’該等藥學組成物，包括慢釋放性形式， 其製備可以使用藥劑師及藥學技術專家所熟知的例行性技 術和設備予以完成。
Claims (1)
- 200526246 (1) 十、申請專利範圍 1· 一種長賓特辛（pentraxin) PTX3的抑制劑或拮抗 劑對於製備預防和治療骨骼和軟骨退化疾病所用藥劑之用 途。 、 2 ·如申請專利範圍第1項之用途，其中該長賓特辛 _ PTX3抑制劑爲能夠結合ΡΊΓΧ3的任何單株或多株抗體。 3 ·如申請專利範圍第2項之用途，其中該抗體爲天 然（人類或動物），重組或合成來源者。 C 4 ·如申請專利範圍第1項之用途，其中該拮抗劑爲 保有選擇性抑制ΡΤΧ3活性的能力之單體物型ΡΤΧ3，或其 肽或肽模擬性衍生物之一者。 5 ·如申請專利範圍第4項之用途，其中該拮抗劑爲 天然（人類或動物），重組或合成來源者。 6 ·如申請專利範圍第4項之用途，其中該單體物型 賓特辛爲人類來源者。 7.如申請專利範圍第1項之用途，其中該自體免疫 · 性疾病爲選自下列所構成的群組之中者：系統性紅斑狼瘡 (S LE )、多發性硬化（M S )、關節炎、糖尿病、甲狀腺 、 炎、溶血性貧血、萎縮性睪九炎、Good pasture氏病、自 體免疫性視網膜病、自體免疫性血小板減少症、重症肌無 力、原發性膽硬化、慢性攻擊性肝炎、漬瘍性結腸炎、皮 炎、慢性血管球性腎炎、Sj0gren氏徵候群、Reiter氏徵 候群、肌炎、系統性硬化及多關節炎。 8 .如申請專利範圍第1項之用途，其中該退化性骨 -12 - 200526246 (2) 縣或軟骨疾病係選自下列所構成的群組之中者：骨關節炎 •’骨關節病；關節退化病；膠原缺乏；具有軟骨內軟化的 特徵之軟骨或骨骼疾病；原發性關節炎，包括，例如，風 濕性關節炎、幼年型關節炎、未分化型慢性關節炎；和多 · 關節炎；自體免疫源的繼發性關節炎，包括，例如，系統 丨生紅斑狼瘡、牛皮癣性關節炎、Crohn氏病關節炎；代謝 不全性來源之關節炎，包括，例如，尿酸一鈉關節病、焦 碟酸鹽關節病、草酸鈣關節病；傳染性關節炎、因骨質疏 ^ 鬆所致關節炎、無菌性骨壞死、良性和惡性骨腫瘤。 -13 - 200526246 七 定 無 明 說 單 簡 號 符 為代 圖件 表元 代之 定圖 指表 案代 本本 八、本案若有化學式時，請揭示最能顯示發明特徵的化學 式：無
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000596A ITRM20030596A1 (it) | 2003-12-23 | 2003-12-23 | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200526246A true TW200526246A (en) | 2005-08-16 |
Family
ID=34708534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093137054A TW200526246A (en) | 2003-12-23 | 2004-12-01 | Medicament comprising inhibitors of long pentraxin PTX3 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070098722A1 (zh) |
| EP (1) | EP1706144A2 (zh) |
| JP (1) | JP2007517021A (zh) |
| CN (1) | CN1893975A (zh) |
| AR (1) | AR047159A1 (zh) |
| AU (1) | AU2004305341A1 (zh) |
| BR (1) | BRPI0418017A (zh) |
| CA (1) | CA2548452A1 (zh) |
| IT (1) | ITRM20030596A1 (zh) |
| MX (1) | MXPA06007080A (zh) |
| TW (1) | TW200526246A (zh) |
| WO (1) | WO2005060997A2 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| WO2007128647A1 (en) | 2006-05-02 | 2007-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION |
| EP2245061A2 (en) * | 2007-12-11 | 2010-11-03 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| CA2894696A1 (en) | 2012-12-21 | 2014-06-26 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
| JP6959913B2 (ja) * | 2016-05-13 | 2021-11-05 | 国立大学法人 東京大学 | 肝分泌型代謝制御因子阻害作用による肥満関連疾患治療剤 |
| CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
| TWI741216B (zh) * | 2017-09-19 | 2021-10-01 | 臻崴生物科技有限公司 | 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US20030195167A1 (en) * | 2002-04-15 | 2003-10-16 | Kowa Co., Ltd. | PTX3-gene expression inhibitor |
-
2003
- 2003-12-23 IT IT000596A patent/ITRM20030596A1/it unknown
-
2004
- 2004-12-01 TW TW093137054A patent/TW200526246A/zh unknown
- 2004-12-21 AU AU2004305341A patent/AU2004305341A1/en not_active Abandoned
- 2004-12-21 US US10/584,292 patent/US20070098722A1/en not_active Abandoned
- 2004-12-21 BR BRPI0418017-8A patent/BRPI0418017A/pt not_active IP Right Cessation
- 2004-12-21 CN CNA2004800371947A patent/CN1893975A/zh active Pending
- 2004-12-21 CA CA002548452A patent/CA2548452A1/en not_active Abandoned
- 2004-12-21 EP EP04806879A patent/EP1706144A2/en not_active Ceased
- 2004-12-21 MX MXPA06007080A patent/MXPA06007080A/es not_active Application Discontinuation
- 2004-12-21 WO PCT/IT2004/000714 patent/WO2005060997A2/en active Application Filing
- 2004-12-21 JP JP2006546487A patent/JP2007517021A/ja active Pending
- 2004-12-21 AR ARP040104816A patent/AR047159A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007517021A (ja) | 2007-06-28 |
| EP1706144A2 (en) | 2006-10-04 |
| US20070098722A1 (en) | 2007-05-03 |
| CA2548452A1 (en) | 2005-07-07 |
| BRPI0418017A (pt) | 2007-04-17 |
| KR20070000415A (ko) | 2007-01-02 |
| CN1893975A (zh) | 2007-01-10 |
| AU2004305341A1 (en) | 2005-07-07 |
| WO2005060997A2 (en) | 2005-07-07 |
| ITRM20030596A1 (it) | 2005-06-24 |
| MXPA06007080A (es) | 2006-09-04 |
| AR047159A1 (es) | 2006-01-11 |
| WO2005060997A3 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Engdahl et al. | Periarticular bone loss in arthritis is induced by autoantibodies against citrullinated vimentin | |
| Du et al. | T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis | |
| JP5822822B2 (ja) | Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用 | |
| Samanta et al. | Rheumatoid arthritis and anaesthesia | |
| IL194987A (en) | Use of PIF peptide to produce a drug to regulate the immune system | |
| JP4234439B2 (ja) | Ｉｌ−１２発現調節剤 | |
| Yoshitaka et al. | Etanercept administration to neonatal SH3BP2 knock‐in cherubism mice prevents TNF‐α‐induced inflammation and bone loss | |
| AU2020313326B2 (en) | Peptide therapeutics for autoimmune diseases and inflammatory diseases | |
| WO2021128027A1 (zh) | TACI-Fc融合蛋白及其用途 | |
| TW200526246A (en) | Medicament comprising inhibitors of long pentraxin PTX3 | |
| JP2021525234A (ja) | 疾患の治療に関する組成物および方法 | |
| Hauser et al. | The effect of anti-rheumatic drugs on the skeleton | |
| US9725484B2 (en) | Methods and compositions for the treatment of bone remodeling disorders | |
| Saviano et al. | New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function | |
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| JP2007516277A (ja) | 軟骨および骨の変性疾患の処置および女性不妊症の処置のための、単独またはｔｓｇ−６と組み合わせてｐｔｘ３を含有する医薬 | |
| SK109997A3 (en) | Eukaryotic initiation factor 5a (eif-5a) mutants | |
| JP2009532334A (ja) | 治療 | |
| Zhang et al. | NgR acts as an inhibitor to axonal regeneration in adults | |
| KR20190131068A (ko) | 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 | |
| KR20060136385A (ko) | 긴 펜트락신 ｐｔｘ３의 억제제를 포함하는 약제 | |
| Cheng et al. | Acyloxyacyl hydrolase deficiency induces chronic inflammation and bone loss in male mice | |
| WO2023027132A1 (ja) | 骨代謝細胞調節剤及びその利用 | |
| US9045553B2 (en) | Cerberus/Coco derivatives and uses thereof | |
| US12098175B2 (en) | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof |